Loading the state's markets…
Loading the state's markets…
Loading the market…
Medicare market size, surgeons and outlook to 2030
Medicare fee-for-service radiofrequency ablation (facet, genicular, basivertebral) cases in Nebraska: reported (2020, the pandemic year, left out of the line), then forecast with its 80% range. One year ahead, this procedure’s market forecast has been off by 4% on average (252 state-years, 2020–2024): a close guide.
| Year | Surgeons | Medicare FFS | Advantage share |
|---|---|---|---|
| 2019 | 28 | 1,868 | 18% |
| 2020 | 31 | 2,005 | 22% |
| 2021 | 33 | 2,449 | 27% |
| 2022 | 33 | 2,512 | 31% |
| 2023 | 35 | 2,421 | 35% |
| 2024 | 37 | 2,646 | 37% |
| 2025 from claims | – | 2,845 2,611–3,010 | 37% |
| 2026 forecast | – | 3,061 2,693–3,532 | 37% |
| 2027 forecast | – | 3,274 2,799–3,901 | 37% |
| 2028 forecast | – | 3,501 2,921–4,287 | 38% |
| 2029 forecast | – | 3,744 3,058–4,696 | 38% |
| 2030 forecast | – | 4,004 3,208–5,131 | 38% |
Facet, genicular, and basivertebral nerve ablation. Professional codes (what the surgeon bills): CPT 64635, 64633, 64624, 64625, 64628.
Surgeons and fee-for-service cases are from CMS’s Medicare Physician & Other Practitioners files, counted where the surgeon billed; state totals include the cases CMS leaves out of the surgeon-level file (under 11 patients). All Medicare adds patients in Medicare Advantage at the state’s enrollment share; all payers scales Medicare by its share of the procedure nationally. The forecast carries cases per resident 65+ forward with the Census projection of residents 65+. How the numbers are made · Data sources
The 10 busiest do 61% of the cases CMS names in Nebraska; 18 surgeons do 80% of them.
MedaRep names every one, ranked by volume, with their practice, hospitals, trend, forecast and which device companies already engage with them.
In 2025, 29% hospital outpatient, 45% surgery center, 27% office.
| State | Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast |
|---|---|---|---|---|---|---|
| Illinois | 165 | 12,036+1%/yr | +1%/yr | 8.4 | 66% | 13,800 in 2030+2.3%/yr |
| Ohio | 179 | 10,830−5.3%/yr | −5.3%/yr | 9.3 | 43% | 11,600 in 2030+1.2%/yr |
| Michigan | 128 | 7,269−3.7%/yr | −3.7%/yr | 8.1 | 75% | 8,240 in 2030+2.1%/yr |
| Indiana | 117 | 6,614−1.7%/yr | −1.7%/yr | 9.0 | 71% | 8,050 in 2030+3.3%/yr |
| Missouri | 93 | 6,170+1.6%/yr | +1.6%/yr | 9.5 | 28% | 8,640 in 2030+5.8%/yr |
| Wisconsin | 107 | 5,630−0.5%/yr | −0.5%/yr | 9.5 | 45% | 6,580 in 2030+2.6%/yr |
| Minnesota | 88 | 4,824+0.9%/yr | +0.9%/yr | 10.1 | 73% | 6,880 in 2030+6.1%/yr |
| Kansas | 57 | 3,413+4%/yr | +4%/yr | 8.2 | 46% | 4,450 in 2030+4.5%/yr |
| Iowa | 36 | 2,386+2.2%/yr | +2.2%/yr | 5.2 | 62% | 2,800 in 2030+2.7%/yr |
| South Dakota | 16 | 1,153−1.6%/yr | −1.6%/yr | 8.6 | 12% | 1,270 in 2030+1.6%/yr |
| North Dakota | 12 | 670−3.9%/yr | −3.9%/yr | 6.5 | 37% | 740 in 2030+1.8%/yr |
| Surgeons | Medicare FFS | Growth since 2019 | Per 1,000 | Out of hospital | Forecast | |
|---|---|---|---|---|---|---|
| Peripheral nerve stimulation & intrathecal pumps | 7 | 421+7.4%/yr | +7.4%/yr | 1.51.4× | 66% | 620 in 2030+6.8%/yr |
| Spinal cord & DRG stimulation | 5 | 200−5.3%/yr | −5.3%/yr | 0.71.0× | 65% | 270 in 2030+5.4%/yr |
Radiofrequency ablation (facet, genicular, basivertebral) in every state, and its device makers · Every procedure market in Nebraska · Every state · Compare with Illinois
Pacira Pharmaceuticals leads with 55% of company spending on these surgeons in 2025, −18 pts on 2024.
In 2025, 5 companies reported engagement with Nebraska’s surgeons worth $47K in consulting, speaking, meals and travel tied to these products, about $1,261 per surgeon billing it. Royalties are left out.
FDA, last 12 months: 2 clearances and approvals in the category, 3 recalled product lines. A recall is a public FDA notice, not a finding of fault.
Which surgeons each company engages, and the dollars reported, are in the ranking. Open Payments shows the payments companies reported. It suggests engagement, not which devices a surgeon uses, and is not evidence of wrongdoing. Every company in the category.
Share of the cases CMS names by surgeon, by where they billed. Open one for its ranking.